Category: PrUMkDeNuR

[Efficacy of grasshoppers_Efficacy and role of grasshoppers]

銆愯殏铓辫彍鐨勫姛鏁坃铓傝毐鑿滅殑鍔熸晥涓庝綔鐢ㄣ€?
鎵€璋撶殑铓傝毐鑿滃苟涓嶆槸澶у鎯宠薄涓敤铓傝毐鍋氱殑鑿滐紝鏄笉鏄湁鍚撲竴璺崇殑鎰熻鍛?鍏跺疄浠婂ぉ瑕佽鐨勮繖涓殏铓辫彍鏄敯闂村湴澶村緢鏄父瑙佺殑椹娇鑻嬶紝瀹冩槸涓€骞寸敓鐨勮崏鏈鐗╋紝鍛抽亾鑲ュ帤澶氭眮锛屽ぇ瀹跺鐢ㄦ潵鍑夋媽銆佹檼骞叉潵椋熺敤锛屽畠鏄竴绉嶅彲浠ラ鐢ㄧ殑閲庤彍锛屼篃鏄竴绉嶈嵂鏉愶紝鏈夌潃娓呯儹瑙f瘨銆佹娉荤殑浣滅敤锛岄偅涔堣殏铓辫彍鐨勫姛鏁堜笌浣滅敤杩樻湁浠€涔堝憿?涓嬮潰涓€璧锋潵浜嗚В涓€涓嬪惂銆?銆佹竻鐑噳琛€娌荤棦銆備富娌荤儹姣掕鐥㈠強婀跨儹鐥㈢柧銆傞┈榻胯媼鑳芥秷闄よ吂閮ㄥ寘鍧楋紝姝㈡秷娓达紝娌荤枟濂充汉璧ょ櫧甯︺€?銆佹秷鐑В姣掓秷鐥堛€傚彲娌荤伀姣掔柈鐤°€傞┈榻胯媼鍏锋湁瑙f瘨銆佹秷鐐庛€佸埄灏裤€佹秷鑲跨殑鍔熸晥銆傚绯栧翱鐥呮湁涓€瀹氳緟鍔╂不鐤椾綔鐢ㄣ€?銆佸埄姘存秷鑲匡紝闄嶄綆琛€鍘嬮┈榻胯媼鍚湁澶ч噺鐨勯捑鐩愶紝鏈夎壇濂界殑鍒╂按娑堣偪浣滅敤;閽剧瀛愯繕鍙洿鎺ヤ綔鐢ㄤ簬琛€绠″涓婏紝浣胯绠″鎵╁紶锛岄樆姝㈠姩鑴夌澹佸鍘氾紝浠庤€岃捣Are you going to be with me?This is not a good idea, but it ‘s not a good idea, but it ‘s not easy to find out what ‘s going on, what ‘s going on, what ‘s going on, what ‘s going on, what ‘s going on, what ‘s going on?闃叉娣嬪反绠″彂鐐庡拰闃绘绾ょ淮鎬у彉鍖栵紝鏉滅粷鐭界粨鑺傚舰鎴愶紝瀵圭櫧鐧滈涔熸湁涓€瀹氱殑鐤楁晥;椹娇瑙夎繕鍚湁杈冨鐨勮儭钀濆崪绱狅紝鑳戒績杩涙簝鐤$梾鐨勬剤鍚堛€?銆 佹 幃 姾 姾 姣 庣 庯 溴 溴 椹 愓 委 凔  鐥 ㈢ 柧 叜 哜 銆 丆 劷 尷 尓 尽 尽 尽 尰 尰 揰 叮叮叮 叮叮叮 叮叮彲鐢ㄤ簬鍚勭鐐庣棁鐨勮緟鍔╂不鐤楋紝绱犳湁鈥滃ぉ鐒舵姉鐢熺礌鈥濅箣绉般€?銆侀┈榻胯媼鍚赴瀵岀殑蠅-3鑴傝偑閰革紝瀵归檷浣庡績琛€绠$梾鐨勫彂鐢熸湁寰堝ソ鐨勪綔鐢ㄣ€?銆 侀 鉆 誯 媪 姹 姸 丸 凞 語 繞 貞 繞 繞 幁 揁 鏄 逄 駄 駄 勪 綔 鐢  纴 鐢 ㄥ 啠 雰 雰 氰 尖 氃 氣 欰 欣 欰 欕 欆What is the best way to mix and match? Do you want to mix it up? Do you want to mix it? Do you want to mix it?鍏ュぇ鑲犲張鍠勬竻鍑夎娌荤棦銆備负琛€鐥€佺柈姣掓墍甯哥敤銆?銆 侀 銆 訯 媪 権 樻 槸 缃 曡 杆 啄 勫 ぉ 鐒 菮 阍 阍 Rhine  鐗 ╋ 纴 鐢 Various 畬 糜 奜 鍐 呯 Self-explaining and fine-grained and difficult to readThe key words are: “Key Key”, “Key Words”, “Hot Words”, “Hot Words”, “Darkness”, “Darkness”, “Darkness”, “Darkness”, “Don’t Go”殑阍惧浜庢甯告按骞炽€?

[How to make cold okra]_Homemade way to make cold okra_Encyclopedia of cold okra_How to make cold okra

锘?

[How to make cold okra]_Homemade way to make cold okra_Encyclopedia of cold okra_How to make cold okra

Have you become accustomed to a dependent life, and have you lost a lot of your abilities?

At least for most people, the ability to cook is now lost.

If you want to be Almighty, you certainly don’t want to be like this.

So, please ask me now to learn how to make cold okra.

1.

Wash the okra, remove the pedicle, and cut into double spares with a knife.

2.

1 chilli noodles, raw soy sauce, oyster sauce, white sugar and garlic, chilli into a bowl of sauce, pour in hot oil to taste.

3.

Boil a pot of water in the 2 pots, put the okra in the pot and simmer for 2 minutes, add salt, the oil can make the okra greener.

4.

Strain the okra into the bowl and drizzle the sauce.

It is not difficult to make this dish of cold okra. The hard thing is whether you have persistence.

In fact, as long as you can thoroughly understand the method steps mentioned above, plus your insistence, the “results” will immediately appear.

BYD (002594) Annual Report Comments: First-quarter 2019 results will significantly improve and continue strong product cycle

BYD (002594) Annual Report Comments: First-quarter 2019 results will significantly improve and continue strong product cycle

The company’s performance in 2018 was in line with expectations and net profit attributable to mothers was achieved.

8 billion companies released their 2018 annual report: 2018 achieved operating income of 1,300.

5.5 billion (+ 22% year-on-year.

79%), net profit attributable to mother 27.

8 billion (YOY-31.

63%), net profit after deduction 5

8.6 billion (YOY-80.

39%); of which, the fourth quarter achieved revenue of 410.

7.3 billion (+ 28% YoY).

43%), net profit attributable to mother 12.

5.武汉夜网论坛3 billion (YOY-1.

72%).

Taking into account that the new energy vehicle business has achieved strong growth compared to the same period in 2018, the company estimates that net profit in the first quarter of 2019 will be 7 ppm to 900 million, an increase of 583.

39% -778.

65%.

We believe that the company, as a global leader in the new energy automotive industry, will continue to benefit from industrial dividends, and the new product cycle will drive brand effects and sales volume-driven scale effects.

We estimate the company’s net profit attributable to its parent to be 32 in 2019-2021.

24/42.

71/53.

22 trillion, corresponding to EPS 1.

18/1.

57/1.

95 yuan, maintaining the “strongly recommended” level.

  A number of new models were launched in 2019, and the product cycle remained strong. In 2018, BYD achieved total vehicle sales of 520,687 units, an increase of 45.

16%.

Among them, the sales of new energy vehicles are expected to increase by 247,811 units, surpassing Tesla in April 2018.

520,000 vehicles were delivered, an increase of 118 per year.

01%, ranking first in the world.

According to GGII data, the company’s new energy passenger car sales in January 2019 were 28,005 vehicles, continuing to maintain the number one position in the world.

The company’s domestic market share of new energy passenger cars in 2018 was 21 in January and February 2019, respectively.

74%, 32.

67% and 27.

84%, stays solid above the faucet.

In 2019, the company’s product strategy launched the e-series and the dynasty series at the same time, including e1, Tang EV, Song Max DM and Yuan EV535, and other models were launched, maintaining high sales growth.

  Adhering to the strategy of opening up to the outside world and continuously showing the value of the supply chain On March 25, 2019, BYD and Huawei signed a comprehensive strategic agreement in Shenzhen. The two parties will cooperate in the areas of automotive intelligent networking, intelligent driving, smart cloud rails, and smart parks.

According to GGII, the company’s power battery delivery volume in 2018 was 14GWh, with a market share of 21.

53%.

In addition, the company will establish a joint venture with Changan Automobile to produce a 10GWh battery factory to supply power batteries for Changan Automobile.For businesses with core competitiveness such as power batteries and IGBT technology applications, the company is expected to accelerate external sales while promoting internal sales while ensuring internal demand, and achieve long-term sustainable development of the business.

  Risk warning: New energy vehicle subsidy policy is withdrawn; competition in the industry is intensified; the risk of fluctuations in raw material prices; the photovoltaic sector business is dragging down performance.

Kelun Pharmaceutical (002422): Three Developments strategy greatly promotes the stock, and the incremental business develops together

Kelun Pharmaceutical (002422): “Three Developments” strategy greatly promotes the stock, and the incremental business develops together
Three-engine-driven, innovation-driven breakthroughs in future development The basic company implements the development strategy of “three-engine-driven, innovative growth”.Through continuous industrial upgrading and variety structure adjustment, maintain the leading position of Kelun in the field of infusion; establish the competitive advantage of the entire industry chain of antibiotics from intermediates, raw materials to preparations;Possible basis for long-term development.The company’s operating income in 2018 was 163.52 ppm, an increase of 43 in ten years.00%, net profit attributable to mother 12.1.3 billion, an increase of 62 in ten years.04%, through the release of the company’s antibiotic intermediate production, while the infusion product structure has continued to optimize, and new products have been approved for listing. Stable consolidation of infusion faucets, continued to promote structural optimization, parenteral nutrition has become a new growth point. After the industry adjustment brought by policies such as “limitation resistance” and outpatient restrictions on infusion, the large infusion industry has gradually built its bottom, and the bottom can basically reflect the rigid demand.In 2018, Kelun Pharmaceutical’s infusion products achieved operating income of 98.80 ppm, an increase of 30 in ten years.37%, gross margin reached 71.18%, Kelun industry accounted for more than 40%, through investing in the equity of Shisi Medicine, further consolidated the industry leader ranking.In terms of structure, the company sells mid-to-high-end standable bags, and soft bags continue to replace low- and medium-end plastic bottles and glass bottles. The company is expected to continue to increase the revenue and profitability of large infusions.In addition, the company has approved 7 parenteral nutrition infusion products in 20苏州夜网论坛17 and 2018, transforming the company’s continuous enrichment of parenteral nutrition products, and is expected to become an important new growth point for the company’s large infusions in the future. Yili Chuanning achieved full production, and new varieties quickly increased in 2018. The company’s antibiotic intermediates and APIs achieved sales revenue of 32.94 ppm, a 79-year increase of 79.62%.Among them, the second-phase technical reform project of the subsidiary Yili Chuanning passed the inspection and acceptance of the Ministry of Environmental Protection, the production capacity was released, and the losses were turned into profit, with a net profit of 6.09 million yuan.Absolute supply-side reforms continue to advance, environmental protection trends continue to be severe, barriers to entry for APIs and intermediates industries are further raised, and the remaining industry trends are king, and companies with cost advantages will further win.This business is the basis for the company’s long-term sustainable development and reduced cash flow; the company has a rich project reserve, and new varieties represented by generic drugs have been continuously approved. Through continuous product descriptions, product substitution can be formed, and the company’s strong recruitment standards are used to enter and sell.Ability to achieve rapid sales growth; gradually realize, actively promote consistent assessment, participate in the centralized procurement and increase contribution, and at the same time strengthen the control of upstream raw materials to form an integrated competitive advantage.In the next 3-5 years, the generic drug segment is expected to be an important driving force for the company’s overall performance growth. Continued high R & D investment and innovation-driven long-term development are marked by the national “4 + 7” belt procurement pilot. The domestic pharmaceutical industry has entered a new era of challenges and opportunities, and innovation will become a key path for the future development of pharmaceutical companies.The company continues to invest in research and development to continuously improve its core competitiveness.The company’s stable profitability and cash flow have created good conditions for the company’s high R & D investment.Since 2012, R & D investment has exceeded USD 4 billion, and R & D investment in 2018 was 11.14 ppm, ranked 6th in the absolute amount of A-share pharmaceutical listed companies, and the compound growth of R & D expenditure in 2012-2018 reached 31%.In 2018, Cologne obtained 5 approvals for clinical trials of innovative drugs, including 2 innovative small molecules and 3 biological macromolecules, and submitted 1 innovative drug IND application to the US FDA, and has been approved for clinical research; KL-A167 entered the keyIn the clinical phase II, KL-A166 injection in China and the United States is underway. Phase I clinical research indicates that Columb’s drug research has entered an international process. The company’s continuous research and development innovation makes up an alternative basis for long-term development. We are optimistic about the company’s development prospects and cover it for the first time. Given a “buy rating”, we expect the EPS for 2019-2021 to be 1.11, 1.40 and 1.71 yuan, corresponding to PE is 24, 19 and 16 times.Combining the absolute valuation method and the segment evaluation method, the company’s reasonable target price for 2019 is 32.3 yuan, optimistic about the company’s future strategy and continuous rapid growth, the first coverage, given a “buy rating”. Risk reminder: the progress of research and development exceeds expectations, the rate of new product volume exceeds expectations, the purchase price of volume drops more than expected, and the risk of changes in the price of APIs in the middle